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Purpose: Recent studies have suggested that renal phosphate leakage and the asso-
ciated phosphaturia are significant underlying causes of calcium urolithiasis. The aims 
of this study were to assess whether phosphaturia relates to urinary metabolic abnor-
malities and recurrent stone formation.
Materials and Methods: A database of patient histories and urine chemistries was ana-
lyzed for 1,068 consecutive stone formers (SFs) and 106 normal controls. Urine values 
for phosphaturia that were higher than 95% of the normal control values were defined 
as indicating hyperphosphaturia, and the effect of phosphaturia on urinary metabolites 
and stone recurrence was determined. Of these patients, 247 patients (23.1%) who had 
been followed up for more than 36 months or had a recurrence of stones during follow-up 
(median, 46.0 months; range, 5-151) were included in the analyses for stone recurrence.
Results: Of the SFs, 19.9% (212/1,068) had increased urinary phosphate excretion. SFs 
with hyperphosphaturia had a greater urinary volume and higher levels of calcium, 
uric acid, oxalate, and citrate than did SFs with normophosphaturia. A multivariate 
Cox regression model, stratified by stone episodes, revealed that hyperphosphaturia 
was an independent predictor of recurrent stone formation in first-time SFs (hazard 
ratio [HR]: 2.122; 95% confidence interval [CI]: 1.100-4.097; p=0.025). No association 
was detected between hyperphosphaturia and recurrent stone formation in recurrent 
SFs. Kaplan-Meier curves showed identical results.
Conclusions: This study demonstrates that hyperphosphaturia is closely associated 
with urinary metabolic abnormalities. Furthermore, hyperphosphaturia is a sig-
nificant risk factor for stone recurrence in first-time SFs.
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INTRODUCTION
Urolithiasis is a common disorder that affects approx-
imately 3-5% of the population and is usually associated 
with metabolic abnormalities [1-3]. Although both in-
trinsic and environmental factors contribute to urinary 
stone formation, the exact cause is not fully understood 
[2-7]. More precise knowledge about the etiology of ur-
olithiasis may contribute to improvements in disease man-
agement and prevention.
Hypercalciuria has been considered to be the most com-
mon abnormality identified in calcium stone formers (SFs) 
[2,3]. Recent studies have suggested that a defect in phos-
phate balance, such as maximal reabsorption of phosphate 
by the glomerular filtration rate (TmP/GFR), is a sig-
nificant underlying cause of calcium urolithiasis [8-11]. 
Reduced renal phosphate reabsorption leads to hypo-
phosphatemia that, in turn, increases 1,25(OH)2-vitamin 
D synthesis and enhances the intestinal absorption of 
phosphate and calcium, resulting in hypercalciuria 
[12-14]. Additionally, mutations in the genes that encode 
two renal sodium phosphate co-transporters, NPT2a and 
NPT2c, have been identified in patients with hyper-
phosphaturia [15,16]. Inactivation of the gene that encodes 
NPT2a results in increased excretion of phosphate and cal-
cium and bone demineralization [17]. Thus, there has been 
increasing interest in the role of renal phosphate handling 
and the associated hyperphosphaturia in stone formation.
Identification of modifiable risk factors for urolithiasis 
may result in new approaches to the treatment and pre-Korean J Urol 2010;51:54-59
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vention of this disorder. The present study was designed 
to assess whether phosphaturia relates to urinary meta-
bolic abnormalities and recurrent stone formation.
MATERIALS AND METHODS
1. Subjects and sample collection
A database of calcium SFs who were diagnosed and treated 
between 1994 and 2008 at our institute was reviewed. The 
database included stone history, medication, and a meta-
bolic evaluation that included serum chemistry, 24-hour 
urinary chemistry, and radiographic imaging of the uri-
nary tract. A diagnosis of calcium stone formation was 
based on an abdominal radiograph and ultrasound 
examination. The metabolic evaluation was performed at 
least 6 weeks after the last stone episode. SFs with any of 
the following conditions were excluded from the analysis: 
pediatric patients (＜16 years), incomplete 24-hour urine 
collection, impaired renal function (serum creatinine ＞1.5 
mg/dl), staghorn calculi, urinary tract obstruction, malfor-
mation of the urological system, hypercalcemia, prior diag-
nosis of primary hyperparathyroidism, or other systemic 
diseases that might affect calcium and bone metabolism. 
Medications that could affect biochemical parameters 
were discontinued 2 weeks before the 24-hour urine 
collection. SFs were told to continue their usual diet, and 
no patient had been placed on a low-calcium diet. Thus, 
1,068 consecutive calcium SFs [706 first-time stone for-
mers (FSFs) and 362 recurrent stone formers (RSFs)] with 
complete metabolic assessments were included in the final 
analysis. Of these, SFs who had been followed up for more 
than 36 months or had stones during the follow-up period 
(median, 46.0 months; range, 5-151 months) were eligible 
for analysis of stone recurrence.
After informed consent was obtained, 106 healthy vol-
unteers (mean age: 42.2±12.8 years [range, 17 to 72 years]; 
67% male [69/106]; 34.7% female [37/106]) who had no evi-
dence of stone disease as confirmed by abdominal radio-
graph and ultrasound examination, unimpaired renal 
function, no history of urological disease, and no medi-
cations were enrolled as controls.
2. Measurement and definition of parameters
All measurements were made by routine methods. In the 
normal controls, 95% of the subjects had a urinary phos-
phate excretion of less than 800 mg/day. Because there is 
no universally accepted definition for hyperphosphaturia, 
any value for phosphaturia that was higher than 95% of the 
control values was defined as indicative of hyper-
phosphaturia [8,9]. Urinary metabolic abnormalities were 
classified into five categories as follows: low urine volume 
(urine volume less than 2,000 ml hypercalciuria (calcium 
greater than 300 mg in males and 250 mg in females), hy-
peroxaluria (oxalate greater than 45 mg), hyperuricosuria 
(uric acid greater than 800 mg in males and 750 mg in fe-
males), and hypocitraturia (citrate less than 320 mg) [3]. 
Stone recurrence was defined as the passage, ex-
tracorporeal removal, endoscopic or surgical removal, or 
radiographic appearance of stones that were not present 
on previous examination. The time to stone recurrence was 
measured from the date the patient was pronounced as be-
ing stone free at our institution to the date of stone relapse 
during the follow-up period or last follow-up.
3. Statistical analyses
To investigate the effect of phosphaturia on urinary metab-
olites and recurrent stone formation, subjects were classi-
fied as SFs with normophosphaturia or as SFs with 
hyperphosphaturia. Differences in the urine variables be-
tween the subgroups were assessed by Student’s t-tests. 
Categorical variables were compared with chi-square 
tests. The Kaplan-Meier method was used to calculate the 
time to recurrence, and differences were assessed with 
log-rank statistics. The prognostic value for the status of 
phosphaturia on stone recurrence was studied with a Cox 
proportional hazards regression model. Cases were ad-
justed for well-known clinical and metabolic prognostic 
factors for recurrence. All statistical analyses were per-
formed with SPSS 12.0 software (SPSS Inc., Chicago, 
USA), and p-values＜0.05 were considered statistically 
significant.
RESULTS
1. Baseline characteristics
The 1,068 patients were grouped according to whether or 
not they had hyperphosphaturia (80.1% of the SFs had nor-
mophosphaturia [856/1,068]; 19.9% of the SFs had hyper-
phosphaturia [212/1,068]). The mean age was significantly 
different between the two groups. Compared with FSFs, 
the incidence of hyperphosphaturia was more common in 
RSFs. The baseline characteristics of the SFs are presented 
in Table 1.
2. Urine parameters
SFs with hyperphosphaturia had greater urinary volume 
and higher levels of calcium, uric acid, oxalate, and citrate 
than did SFs with normophosphaturia. The mean urinary 
pH was lower in SFs with hyperphosphaturia than in SFs 
with normophosphaturia. Subgroup analyses, grouped by 
stone episodes, also showed similar results (Table 2).
3. Status of phosphaturia and stone recurrence
Two hundred forty-seven (23.1%) SFs were eligible for 
analysis of recurrent stone formation (21.1% of the FSFs 
[149/706] and 27.1% of the RSFs [98/362]). During the fol-
low-up period, 62.3% (154/247) had recurrent stones 
(57.0% of the FSFs [85/149] vs. 70.4% of the RSFs [69/98], 
p=0.034). Kaplan-Meier estimates revealed significant dif-
ferences in the prevalence of recurrent stone formation be-
tween patients with hyperphosphaturia and those with 
normophosphaturia (log-rank test, p=0.032) (Fig. 1A). 
Stratified by stone episodes, FSFs with hyperphospha-
turia had a shorter time to stone recurrence than did FSFs Korean J Urol 2010;51:54-59
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FIG. 1. Kaplan-Meier curve estimates of the probability of stone recurrence in relation to phosphaturia status for (A) all stone formers 
(n=247) and (B) first-time stone formers (n=149).
TABLE 1. Baseline characteristics of the study populations
Parameters Normophosphaturia (n=856) Hyperphosphaturia (n=212) p-value 
Age (years)
a
Sex (%)
   Male
   Female
No. of family history of stone (%)
   No
   Yes
No. of stone episode (%)
   FSF
   RSF
No. of stone (%)
   Single
   Multiple
44.6±12.8
542 (63.3)
314 (36.7)
705 (82.4)
151 (17.6)
580 (67.8)
276 (32.2)
667 (80.2)
189 (80.1)
41.8±10.7
173 (81.6)
39 (18.4)
171 (80.7)
41 (19.3)
126 (59.4)
86 (40.6)
165 (19.8)
47 (19.9)
　0.022
b
＜0.001
c
　0.564
c
　0.022
c
　0.977
c
FSF: first-time stone formers, RSF: recurrent stone formers, 
a: Mean±SD, 
b: Student’s t-test, 
c: chi-square test
TABLE 2. Baseline urine chemistries and phosphaturia status for patients with urolithiasis
Variables
Totals FSF RSF
N (n=856) H (n=212) p-value N (n=580) H (n=126) p-value N (n=276) H (n=86) p-value
Total volume (cc/day)
pH
Sodium (mEq/day)
Calcium (mg/day)
Uric acid (mg/day)
Oxalate (mg/day)
Citrate (mg/day)
1,748±643
6.27±0.97
196±79
196±95
603±171
30±29
358±218
2,031±739
6.07±0.91
255±85
275±116
856±227
34±30
455±269
＜0.001
　0.011
＜0.001
＜0.001
＜0.001
　0.044
＜0.001
1,763±676
6.31±0.98
194±79
192±93
600±176
30±32
356±231
2,020±758
6.10±0.90
257±78
264±110
875±233
32±27
456±276
＜0.001
　0.026
＜0.001
＜0.001
＜0.001
　0.415
＜0.001
1,717±567
6.16±0.94
203±78
203±98
610±164
30±22
360±220
2,047±716
6.03±0.94
251±95
289±124
829±218
37±34
454±260
＜0.001
　0.296
＜0.001
＜0.001
＜0.001
　0.016
　0.001
FSF: first-time stone formers, RSF: recurrent stone formers, N: normophosphaturia, H: hyperphosphaturia
with normophosphaturia (log-rank test, p=0.010) (Fig. 
1B), whereas the time to recurrence was not affected by hy-
perphosphaturia in the RSFs (log-rank test, p=0.931). 
Multivariate Cox regression analyses that included known 
clinical (mean age at stone onset, sex, stone episodes, fam-
ily history of stones, and stone multiplicity) and metabolic 
(low urine volume, hypercalciuria, hyperuricosuria, hy-
peroxaluria, and hypocitraturia) risk factors for stone re-
currence revealed that hyperphosphaturia (hazard ratio 
[HR]: 1.718; 95% confidence interval [CI]: 1.090-2.707; Korean J Urol 2010;51:54-59
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TABLE 3. Multivariate Cox regression analyses for the prediction of stone recurrence in relation to phosphaturia status
Variables
Totals (n=247) FSF (n=149) RSF (n=98)
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age
Sex
Stone episodes
Family history
Multiplicity
Hyperphosphaturia
Low urine volume
Hypercalciuria
Hyperuricosuria
Hyperoxaluria
Hypocitraturia
0.686 (0.484-0.974)
0.906 (0.614-1.336)
1.550 (1.104-2.176)
0.952 (0.629-1.441)
0.955 (0.643-1.419)
1.718 (1.090-2.707)
0.851 (0.599-1.211)
1.001 (0.658-1.524)
1.613 (1.018-2.554)
0.778 (0.554-1.094)
1.206 (0.850-1.712)
0.035
0.618
0.011
0.814
0.821
0.020
0.371
0.996
0.042
0.778
0.294
0.729 (0.451-1.177)
0.920 (0.543-1.558)
−
0.800 (0.442-1.450)
0.953 (0.495-1.835)
2.122 (1.100-4.097)
0.791 (0.487-1.284)
0.807 (0.468-1.393)
1.169 (0.645-2.119)
0.689 (0.432-1.096)
1.104 (0.673-1.811)
0.196
0.757
−
0.462
0.462
0.025
0.343
0.442
0.608
0.116
0.696
0.539 (0.307-0.944)
0.968 (0.504-1.858)
−
1.032 (0.546-1.951)
1.035 (0.594-1.805)
1.427 (0.715-2.850)
0.839 (0.489-1.438)
1.534 (0.776-3.034)
2.806 (1.222-6.444)
0.937 (0.539-1.628)
1.255 (0.708-2.225)
0.031
0.922
−
0.923
0.902
0.313
0.522
0.218
0.015
0.818
0.436
FSF: first-time stone formers, RSF: recurrent stone formers, HR: hazard ratio, CI: confidence interval
p=0.020) was significantly associated with stone re-
currence in SFs. Stratified by stone episodes, hyper-
phosphaturia (HR: 2.122; 95% CI: 1.100-4.097; p=0.025) 
was the only independent predictor for stone recurrence in 
FSFs. In contrast, hyperphosphaturia was not associated 
with stone recurrence in RSFs (Table 3).
DISCUSSION
Recently, several studies have shown that patients with 
idiopathic hypercalciuria have phosphaturia or renal 
phosphate leakage [8,9,12,16]. Renal phosphate leakage 
and the associated phosphaturia result in increased pro-
duction of 1,25(OH)2-vitamin D3, which causes increased 
intestinal phosphate and calcium absorption. The combi-
nation of hyperphosphaturia and hypercalciuria from the 
increased intestinal calcium absorption favors the for-
mation of calcium phosphate complexes that can result in 
urolithiasis [11]. In a previous study, 19% of SFs had renal 
phosphate leakage, defined as renal phosphate threshold 
values lower than 95% of the normal control population, 
which was associated with high urinary calcium excretion 
[8]. Similarly, our results showed that the incidence of hy-
perphosphaturia was 19.9%, which partly supports find-
ings showing that renal phosphate leakage is frequently 
detected in patients with stone disease.
Studies of phosphate excretion have shown that phos-
phaturia plays a key role in stone formation [18,19]. 
Calcium phosphate crystals are injurious to cells of the 
proximal tubules and the collecting ducts. Calcium phos-
phate crystals can interact with the renal epithelium, pro-
mote sites for crystal attachment, and then either grow into 
mature calcium phosphate stones or create sites for cal-
cium oxalate crystal formation, allowing calcium oxalate 
crystals to grow into clinically significant kidney stones 
[18,19]. In our study with long-term follow-up of patients, 
hyperphosphaturia significantly affected not only urinary 
metabolites but also recurrent stone formation. Although 
the exact biological mechanism is still not known, the re-
sults of previous studies provide possible explanations 
[8,16-22]. Impaired renal phosphate reabsorption in-
creases the risks of nephrolithiasis and bone demineraliza-
tion [8,9,16,17]. More recently, several reports suggested 
that the renal phosphate transporters are an important 
cause of phosphaturia in patients with urolithiasis 
[17,20-22]. NPT2a is present in the apical membrane of the 
renal proximal convoluted tubule and is responsible for re-
absorption of 80% of the phosphates filtered at the glomer-
ulus [20]. Regardless of the serum phosphate concen-
tration, phosphate is freely filtered across the glomerulus 
and reabsorbed along the renal tubule, primarily the prox-
imal tubule, through two distinct sodium phosphate trans-
porters that are dependent on the sodium gradient [11]. 
Thus, inactivation of associated genes results in increased 
excretion of phosphate and calcium [17]. In addition, the 
sodium-hydrogen exchanger regulatory factor 1 (NHERF1) 
can interact with known amino acid sequences at the C-ter-
minal end of NPT2a, which induces alteration of NPT2a 
targeting [23,24]. Targeted gene deletion of NHERF1 pro-
vokes not only increased excretion of phosphate, calcium, 
and uric acid, but also interstitial deposition of calcium, pri-
marily in the papilla of the kidney, which are prone to the 
formation of calcium stones, uric acid stones, or both [21]. 
These findings support our results showing that hyper-
phosphaturia was significantly associated with increased 
urinary excretion of calcium and uric acid as well as stone 
recurrence. However, it is uncertain why hyperphospha-
turia was associated with recurrent stone formation only 
in FSFs. There have been several reports of metabolic dif-
ferences, such as urinary excretion of citrate, uric acid, and 
urine volume, between FSFs and RSFs [7,25]. These differ-
ences may lead to the inconsistent effect of hyperphospha-
turia on recurrent stone formation in FSFs and RSFs. Our 
data also demonstrated that hyperuricosuria was an in-
dependent risk factor predicting recurrent stone formation 
in RSFs. This finding is supported by earlier reports [7,26].
Uric acid crystals act as a nidus for calcium oxalate 
stone formation by altering the solubility or precipitation Korean J Urol 2010;51:54-59
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product of calcium and oxalate in solution [22,27]. A recent 
study also indicated that NHERF1 interacts with the 
mouse urate transporter 1 (mURAT1) to regulate uric acid 
transport in the renal proximal tubule and that uric acid 
excretion is increased in NHERF1-knockout mice [22]. 
Patients with gout display a significantly reduced tubular 
reabsorption of phosphate and renal phosphate threshold, 
which results in hyperphosphaturia [28]. These observat-
ions support our findings of a close relationship between 
hyperphosphaturia and increased urinary excretion of uric 
acid. However, it is unclear why hyperphosphaturia was 
closely correlated with other urinary metabolites, such as 
urine volume, pH, oxalate, and citrate, in our results. These 
associations may be due to not only various loads of dietary 
phosphate, but also the existence of currently unidentified 
mechanisms or interactions. Dietary factors are suggested 
to be the major sources of urinary phosphate excretion [29]. 
Accordingly, this may cause the paradoxically increased 
excretion of citrates and urine volume, which are well- 
known urinary stone inhibitory factors, in SFs with 
hyperphosphaturia. Further research is needed to uncover 
these relations.
In the clinical setting, identification of meaningful, 
modifiable risk factors is useful for reducing the prevalence 
of recurrent stone formation. Our results suggest that hy-
perphosphaturia is an independent, predictive determi-
nant of stone recurrence. In this regard, manipulation of 
renal phosphate excretion may prove valuable. For exam-
ple, administration of thiazide reduces calcium and phos-
phate excretion, whereas oxalate excretion increases sig-
nificantly [30]. Because a calcium phosphate solid phase 
seems to be the initial mineralization event in patients 
with calcium oxalate stones, thiazide may prevent re-
current calcium oxalate stones by reducing calcium phos-
phate supersaturation [30]. Appropriate control of phos-
phaturia in patients with hyperphosphaturia may be a 
promising approach for restoring normal urine composi-
tion and reducing the number of stone episodes.
CONCLUSIONS
The results of this study demonstrate that hyperphospha-
turia is closely associated with urinary metabolic abnor-
malities. Furthermore, hyperphosphaturia is a significant 
risk factor for recurrent stone formation in FSFs. Phospha-
turia could be a useful factor for predicting metabolic ab-
normalities and stone recurrence.
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